Childhood B cell leukemia: Intercepting the paths to progression.

Autor: Cobaleda C; Immune System Development and Function Unit, Centro de Biología Molecular Severo Ochoa (CBM, CSIC-UAM), Madrid, Spain., Vicente-Dueñas C; Institute for Biomedical Research of Salamanca (IBSAL), Department of Pediatrics, Hospital Universitario de Salamanca, Salamanca, Spain., Nichols KE; Division of Cancer Predisposition, St. Jude Children's Research Hospital, Memphis, Tennessee, USA., Sanchez-Garcia I; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Salamanca, Spain.
Jazyk: angličtina
Zdroj: BioEssays : news and reviews in molecular, cellular and developmental biology [Bioessays] 2024 Sep; Vol. 46 (9), pp. e2400033. Date of Electronic Publication: 2024 Jul 26.
DOI: 10.1002/bies.202400033
Abstrakt: B-cell Acute Lymphoblastic Leukemia (B-ALL) is the most common pediatric cancer, arising most often in children aged 2-5 years. This distinctive age distribution hints at an association between B-ALL development and disrupted immune system function during a susceptible period during childhood, possibly triggered by early exposure to infection. While cure rates for childhood B-ALL surpass 90% in high-income nations, survivors suffer from diminished quality of life due to the side effects of treatment. Consequently, understanding the origins and evolution of B-ALL, and how to prevent this prevalent childhood cancer, is paramount to alleviate this substantial health burden. This article provides an overview of our current understanding of the etiology of childhood B-ALL and explores how this knowledge can inform preventive strategies.
(© 2024 The Author(s). BioEssays published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: